NEW YORK—Marina Maher Communications has added Q-Med Scandinavia’s Deflux to its healthcare practice client roster. Deflux is a leading international treatment method and the only product approved in the U.S. for children with vesicoureteral reflux, a malformation of the bladder that can cause recurrent infections and kidney damage.
“We were impressed with Marina Maher Communications’ winning combination of strong professional capabilities and keen consumer insights—both essential to our goal of educating physicians and parents about Deflux,” says Mark Altenburger, senior marketing manager for Q-Med Scandinavia. “The agency’s strategic thinking, as well as its creativity and enthusiasm, were key factors in our decision to award MMC the business.”
Q-Med is a growing biotechnology and medical device company with head office and production facilities in Uppsala, Sweden.